Alpha 2.0
Login Register
» Authors » David H Xiang

David H Xiang

Explore the profile of David H Xiang including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 18
Citations 18
Followers 0
Related Specialties
Dermatology
General Medicine
General Surgery
Top 10 Co-Authors
Nicholas Theodosakis
Yevgeniy Semenov
John Trinidad
Arash Mostaghimi
Katherine Young
Rachel Levine
Gideon P Smith
Kanika Kamal
Sophia Neman
Dimitrios Spentzos
Published In
J Am Acad Dermatol
Arch Dermatol Res
Acad Radiol
Plast Reconstr Surg Glob Open
Am J Hematol
Affiliations
Soon will be listed here.
Recent Articles
1.
Association between provider characteristics and patient no-shows: a retrospective cross-sectional analysis
Xiang D, Neman S, Levine R, Smith G, Chen S, Trinidad J
Arch Dermatol Res . 2024 Aug; 316(8):591. PMID: 39215858
No abstract available.
2.
Impact of insurance status on treatment choice and hospitalization rates in bullous pemphigoid patients: a retrospective cross-sectional analysis
Xiang D, Holt A, Thompson B, Ebriani J, Brumbaugh B, Reardon R, et al.
Arch Dermatol Res . 2024 Aug; 316(8):526. PMID: 39153021
No abstract available.
3.
National trends in multimodality keloid treatment claims from 2017-2020: An IBM Marketscan study
Xiang D, Cheng D, Ji H, Semenov Y, Theodosakis N
J Am Acad Dermatol . 2024 Aug; 91(6):1211-1214. PMID: 39122213
No abstract available.
4.
A retrospective cross-sectional analysis of predictors of patient no-shows in adult outpatient dermatology
Xiang D, Neman S, Levine R, Smith G, Trinidad J
J Am Acad Dermatol . 2024 Jul; 91(4):759-762. PMID: 38950701
No abstract available.
5.
A dynamic microRNA profile that tracks a chemotherapy resistance phenotype in osteosarcoma. Implications for novel therapeutics
Lietz C, Newman E, Kelly A, Xiang D, Zhang Z, Ramavenkat N, et al.
medRxiv . 2024 Jul; PMID: 38946948
Osteosarcoma is a rare primary bone tumor for which no significant therapeutic advancement has been made since the late 1980s despite ongoing efforts. Overall, the five-year survival rate remains about...
6.
Characterization of adverse cutaneous effects in the setting of enfortumab vedotin for metastatic urothelial carcinoma: A retrospective review
Malik R, Xiang D, Riew G, Sanchez-Melendez S, Afvari S, LeBoeuf N, et al.
J Am Acad Dermatol . 2024 Jun; 91(4):753-755. PMID: 38909660
No abstract available.
7.
Differences in patient characteristics for virtual and in-person outpatient dermatology visits: a retrospective cross-sectional analysis
Xiang D, Neman S, Levine R, Smith G, Trinidad J
Arch Dermatol Res . 2024 Jun; 316(7):422. PMID: 38904839
No abstract available.
8.
Racial and ethnic differences in melasma treatment patterns: a multi-institution study
Getachew E, Kamal K, Young K, Xiang D, Semenov Y, Mostaghimi A, et al.
Arch Dermatol Res . 2024 May; 316(5):175. PMID: 38758256
No abstract available.
9.
A case-control study of racial differences in melasma risk factors and incidence in a diverse national United States population
Getachew E, Kamal K, Young K, Xiang D, Semenov Y, Mostaghimi A, et al.
J Am Acad Dermatol . 2024 May; 91(3):539-541. PMID: 38729433
No abstract available.
10.
Investigating price trends and cost-saving opportunities for prescription of topical calcineurin inhibitors using the Truven Marketscan Database
Xiang D, Ji H, Cheng D, Semenov Y, Theodosakis N
J Am Acad Dermatol . 2024 Apr; 91(2):356-359. PMID: 38642858
No abstract available.